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REPLY
We appreciate the interest shown by Drs Finsterer and
Zarrouk-Mahjoub in our study.1 Although we agree with
the comments made on the mode of transmission of sev-
eral mtDNA-associated disorders, the analysis of the fam-
ilies and the patterns of inheritance were beyond the
scope of our study.
As we stated in the Discussion, we do admit the possi-
bility of a selection bias towards mitochondrial disorders
with skeletal muscle involvement. However, we did not
base our inclusion criteria on the existence of suggestive
histological features. Instead, we selected all the patients
with a molecularly confirmed diagnosis who also had a
muscle biopsy performed and analyzed at the neuropathol-
ogy unit that participated in this study, regardless of the
results of the histology. Moreover, as per the supplemen-
tary tables, this study included several patients with pre-
dominant central nervous system or multisystem features
who probably had a muscle biopsy only because it was
more straightforward than obtaining other tissue for
analysis.
We agree that it would be invaluable to have more
detailed clinical information about these patients and
that the source of clinical information in this study is
indeed an important drawback, something we ourselves
pointed out in the Discussion. We also acknowledge the
potential value of biochemical and molecular data
derived from the analysis of other tissues. Nevertheless,
despite the limitations, we believe the results provided
by this study fulfill our major objectives which were, on
one hand, to offer a broad clinical description and to
indentify the most frequent clinical features and, on the
other hand, to analyze the relative diagnostic utility of
both muscle histological analysis and respiratory chain
enzyme assay in patients with suspected mitochondrial
disorders. Unfortunately, the study design did not allow
us to provide follow-up data, and, therefore, it precluded
us from drawing any conclusion on the progression of
these patients.
We believe that it is important to clarify that we have
not stated that muscle biopsy worsens with age because
we do not have follow-up analysis of our patients.
Instead, our results suggest that older patients are more
likely to show histological features of mitochondrial dis-
orders than younger subjects.
We have, indeed, analyzed a group of 183 patients
with mitochondrial histological features independently
of their molecular diagnosis. In 98 of these subjects, a
molecular diagnosis was pursued, and, in 46, a diagnosis
was established. It was decided not to include this analy-
sis because we thought that this might have made our
report less clear for the reader.
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